Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN L FLAMM

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1912937244
CMS profile
86272
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$189,250.35

125 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN L FLAMM

NPI 1912937244 · CMS profile ID 86272

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912937244?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN L FLAMM, NPI 1912937244, CMS profile ID 86272. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912937244?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STEVEN L FLAMM, NPI 1912937244, CMS profile ID 86272. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912937244?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STEVEN L FLAMM, NPI 1912937244, CMS profile ID 86272, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1912937244?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

125 matching records · $189,250.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 125 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–125 of 125.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $1,250.0005/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794478613 CMS
Gilead Sciences, Inc. $2,840.0005/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845881975 CMS
Mallinckrodt Hospital Products Inc. $715.0005/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407621 CMS
Intercept Pharmaceuticals, Inc. $520.0005/03/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836205965 CMS
Gilead Sciences, Inc. $900.0004/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845853583 CMS
Mallinckrodt Hospital Products Inc. $3,575.0004/28/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407615 CMS
Gilead Sciences, Inc. $1,690.0004/20/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845881973 CMS
Gilead Sciences, Inc. $46.5604/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848194299 CMS
Mallinckrodt Hospital Products Inc. $3,575.0003/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407611 CMS
Gilead Sciences, Inc. $2,710.0003/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845881971 CMS
Gilead Sciences, Inc. $1,780.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845853581 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,400.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850304967 CMS
Gilead Sciences, Inc. $1,780.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845853579 CMS
Gilead Sciences, Inc. $400.0003/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845853577 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.9203/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850313347 CMS
Mallinckrodt Hospital Products Inc. $5,005.0003/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407607 CMS
AbbVie Inc. $13.0602/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794478609 CMS
Gilead Sciences, Inc. $4,740.0002/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845881969 CMS
AbbVie Inc. $4,375.0002/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794478605 CMS
Intercept Pharmaceuticals, Inc. $7,020.0002/08/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836205963 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $700.0001/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850133475 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,400.0001/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850328231 CMS
AbbVie Inc. $1,875.0001/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794478601 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.3901/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849961091 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.4501/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850299773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $192,512.08 201
PY2020 $141,660.98 85
PY2021 $189,250.35 125
PY2022 $112,639.07 85
PY2023 $105,325.94 88
PY2024 $209,459.38 153
PY2025 $339,295.04 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $89,359.29 30
PY2024 Principal investigator $56,021.28 18
PY2023 Principal investigator $240.00 1
PY2022 Principal investigator $4,398.34 2
PY2021 Principal investigator $50,277.17 17
PY2020 Principal investigator $37,308.00 16
PY2019 Principal investigator $82,218.91 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $1,857.06 12/19/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237660
Principal investigator 1 Madrigal Pharmaceuticals $1,857.06 11/25/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237656
Principal investigator 1 Madrigal Pharmaceuticals $1,014.00 10/23/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237653
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,014.00 10/14/2025 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171006
Principal investigator 1 Intercept Pharmaceuticals, Inc. $9,887.00 09/18/2025 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171004
Principal investigator 1 Madrigal Pharmaceuticals $2,359.80 09/18/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237648
Principal investigator 1 Madrigal Pharmaceuticals $1,282.50 09/04/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237628
Principal investigator 1 Madrigal Pharmaceuticals $650.00 09/04/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237633
Principal investigator 1 Madrigal Pharmaceuticals $1,687.00 09/04/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237637
Principal investigator 1 Madrigal Pharmaceuticals $3,250.00 09/04/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237640
Principal investigator 1 Madrigal Pharmaceuticals $1,014.00 09/04/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237644
Principal investigator 1 Madrigal Pharmaceuticals $2,359.80 08/21/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237624
Principal investigator 1 Madrigal Pharmaceuticals $1,014.00 08/14/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237612
Principal investigator 1 Madrigal Pharmaceuticals $3,642.30 08/14/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237615
Principal investigator 1 Madrigal Pharmaceuticals $1,282.50 08/14/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237620
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,014.00 07/25/2025 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171002
Principal investigator 1 Madrigal Pharmaceuticals $2,103.30 06/12/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237607
Principal investigator 1 Madrigal Pharmaceuticals $2,103.30 05/28/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237603
Principal investigator 1 Madrigal Pharmaceuticals $2,359.80 05/15/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237600
Principal investigator 1 Madrigal Pharmaceuticals $4,340.05 04/28/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237584
Principal investigator 1 Madrigal Pharmaceuticals $8,505.00 04/28/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237588
Principal investigator 1 Madrigal Pharmaceuticals $8,505.00 04/28/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237591
Principal investigator 1 Madrigal Pharmaceuticals $8,505.00 04/28/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237595
Principal investigator 1 Madrigal Pharmaceuticals $877.50 04/10/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237576
Principal investigator 1 Madrigal Pharmaceuticals $1,014.00 04/10/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237580
Principal investigator 1 Madrigal Pharmaceuticals $2,359.80 04/08/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237572
Principal investigator 1 Madrigal Pharmaceuticals $6,625.40 03/06/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237563
Principal investigator 1 Madrigal Pharmaceuticals $1,134.00 03/06/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237568
Principal investigator 1 Madrigal Pharmaceuticals $3,714.12 02/06/2025 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237559
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,028.00 01/16/2025 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171000